ArticleCancer discovery2017
BCL6 Antagonizes NOTCH2 to Maintain Survival of Human Follicular Lymphoma Cells.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer discovery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 49 citations in OpenAlex.
- Trial
- SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities.Cancer discovery · 2026Article
- miR-155 aberrant expression impairs tumor rejection because of its targeting of ICOSL and multiple pathways implicated in the antitumor response.Pharmacological reviews · 2026Review
- Biology as vulnerability in follicular lymphoma: genetics, epigenetics, and immunogenetics.Blood · 2025Review
- Splenic fibroblasts control marginal zone B cell movement and function via two distinct Notch2-dependent regulatory programs.Immunity · 2025Article
- Notch2 controls developmental fate choices between germinal center and marginal zone B cells upon immunization.Nature communications · 2024Article
- Molecular classification and therapeutics in diffuse large B-cell lymphoma.Frontiers in molecular biosciences · 2023Review
- Modeling the crosstalk between malignant B cells and their microenvironment in B-cell lymphomas: challenges and opportunities.Frontiers in immunology · 2023Review
- Advances in the multi-omics landscape of follicular lymphoma.International journal of biological sciences · 2023Review
- B-cell Lymphoma 6 (BCL6): From Master Regulator of Humoral Immunity to Oncogenic Driver in Pediatric Cancers.Molecular cancer research : MCR · 2022Review
- Comparison of Morphological and Digital-Assisted Analysis for BCL6 Endometrial Expression in Women with Endometriosis.Journal of clinical medicine · 2022Article
- MEF2C opposes Notch in lymphoid lineage decision and drives leukemia in the thymus.JCI insight · 2022Article
- Stromal Notch ligands foster lymphopenia-driven functional plasticity and homeostatic proliferation of naive B cells.The Journal of clinical investigation · 2022Article
- Article
- Transcriptional inhibition of miR-486-3p by BCL6 upregulates Snail and induces epithelial-mesenchymal transition during radiation-induced pulmonary fibrosis.Respiratory research · 2022Article
- Progress toward B-Cell Lymphoma 6 BTB Domain Inhibitors for the Treatment of Diffuse Large B-Cell Lymphoma and Beyond.Journal of medicinal chemistry · 2021Article
- Mouse Models in the Study of Mature B-Cell Malignancies.Cold Spring Harbor perspectives in medicine · 2021Review
- Notch activation is pervasive in SMZL and uncommon in DLBCL: implications for Notch signaling in B-cell tumors.Blood advances · 2021Article
- Mouse Models of Germinal Center Derived B-Cell Lymphomas.Frontiers in immunology · 2021Review
- Ibrutinib resistance in a patient with transformed diffuse large B-cell lymphoma from primary pulmonary mucosa-associated lymphoid tissue lymphoma.Cancer biology & therapy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 7 institutions in 4 countries.
Ester VallsDivision of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, New York.
Camille LobryDepartment of Pathology and Perlmutter Cancer Center, New York University School of Medicine, New York, New York.
Huimin GengDivision of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, New York.
Ling WangDivision of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, New York.
Mariano CardenasDivision of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, New York.
Martín RivasDivision of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, New York.
Leandro CerchiettiDivision of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, New York.
Philmo OhDepartment of Pathology and Perlmutter Cancer Center, New York University School of Medicine, New York, New York.
Shao Ning YangDivision of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, New York.
Erin OswaldDivision of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, New York.
Camille W GrahamDivision of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Yanwen JiangDivision of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, New York.
Katerina HatziDivision of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, New York.
Xabier AgirreDivision of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, New York.
Eric PerkeyLife Sciences Institute, Division of Hematology-Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan.
Zhuoning LiDivision of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, New York.
Wayne TamDepartment of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York.
Kamala BhattDepartment of Pathology and Perlmutter Cancer Center, New York University School of Medicine, New York, New York.
John P LeonardDivision of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, New York.
Patrick A Zweidler-McKayDivision of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Ivan MaillardLife Sciences Institute, Division of Hematology-Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan.
Olivier ElementoInstitute for Computational Biomedicine, Weill Cornell Medical College, New York, New York.
Weimin CiDivision of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, New York. amm2014@med.cornell.edu iannis.aifantis@nyumc.org ciwm@big.ac.cn.
Iannis AifantisDepartment of Pathology and Perlmutter Cancer Center, New York University School of Medicine, New York, New York. amm2014@med.cornell.edu iannis.aifantis@nyumc.org ciwm@big.ac.cn.
Ari MelnickDivision of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, New York. amm2014@med.cornell.edu iannis.aifantis@nyumc.org ciwm@big.ac.cn.
Cornell University · USNew York University · USThe University of Texas MD Anderson Cancer Center · USUniversity of Michigan · USMemorial Sloan Kettering Cancer Center · USUniversité Paris-Sud · FRUniversity of California, San Francisco · US
Funding
Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ADRIANA HEGUY · 1985 to 2026
$83.1MMICHIGAN MEDICAL SCIENTIST TRAINING PROGRAMT32GM007863 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI COLLINS, KATHLEEN L. · 1985 to 2024
$38.3MRole of TET2 mutations in malignant transformation and acute myeloid leukemiaR01CA173636 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI AIFANTIS, IANNIS, LEVINE, ROSS L · 2013 to 2022
$6.3MNotch Signaling in AlloimmunityR01AI091627 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI PEAR, WARREN S · 2011 to 2025
$6.0MThe role of the SCF/FBW7 ubiquitin ligase complex in hematopiesis and leukemia.R01CA133379 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI AIFANTIS, IANNIS · 2009 to 2018
$3.6MMolecular Targeting of Diffuse Large B-cell LymphomaR01CA143032 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI MELNICK, ARI M. · 2010 to 2014
$2.8MThe identification and validation of mechanisms and biomarkers for relapse in diffuse large B-cell lymphoma (Administrative Supplement)R01CA194547 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI ELEMENTO, OLIVIER, TAM, WAYNE · 2015 to 2019
$2.6MTranscriptional silencing by the BCL6 oncoproteinR01CA104348 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI MELNICK, ARI M. · 2004 to 2014
$2.6MThe cohesin complex as a tumor suppressor in myeloid leukemiaR01CA216421 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI AIFANTIS, IANNIS, LEVINE, ROSS L · 2017 to 2021
$2.5MMapping cancer micro-environments for acute leukemiaR01CA202025 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI AIFANTIS, IANNIS, SCHWAB, SUSAN RUTH · 2016 to 2020
$2.3MLong non-coding RNAs in hematopoiesis and blood malignancyR01CA194923 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI AIFANTIS, IANNIS · 2015 to 2019
$2.3MMechanisms of T cell leukemia induction and maintenanceR01CA149655 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI AIFANTIS, IANNIS · 2010 to 2015
$2.0MNCI NIH HHS P30 CA016087NCI NIH HHS R01 CA104348NCI NIH HHS R01 CA133379NCI NIH HHS R01 CA143032NCI NIH HHS R01 CA149655NCI NIH HHS R01 CA169784NCI NIH HHS R01 CA173636NCI NIH HHS R01 CA194547NCI NIH HHS R01 CA194923NCI NIH HHS R01 CA202025NCI NIH HHS R01 CA216421NIAID NIH HHS R01 AI091627NIGMS NIH HHS T32 GM007863
Abstract
Although the BCL6 transcriptional repressor is frequently expressed in human follicular lymphomas (FL), its biological role in this disease remains unknown. Herein, we comprehensively identify the set of gene promoters directly targeted by BCL6 in primary human FLs. We noted that BCL6 binds and represses
Indexed as
AnimalsB-LymphocytesGene Expression Regulation, NeoplasticGerminal CenterHeterograftsHumansLymphoma, FollicularMiceMice, SCIDProto-Oncogene Proteins c-bcl-6Receptor, Notch2BCL6 protein, humanNOTCH2 protein, humanProto-Oncogene Proteins c-bcl-6Receptor, Notch2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.